查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813887

轉氨酶檢測市場規模、佔有率和趨勢分析報告：按檢測類型、技術、最終用途、地區和細分市場預測，2025 年至 2033 年

Transaminase Test Market Size, Share & Trends Analysis Report By Test Type, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

轉氨酶檢測市場摘要

預計 2024 年全球轉氨酶檢測市場價值將達到 41 億美元，到 2033 年預計將達到 78.1 億美元，2025 年至 2033 年的複合年成長率為 7.54%。

市場以AST（天門冬胺酸轉氨酶）和GOT（麩胺酸轉氨酶）等快速且準確的診斷平台為主，廣泛用於肝功能評估、疾病監測和一般健康篩檢。

隨著人們對肝病的認知不斷提高，以及這些平台在醫院、診所和照護現場的廣泛應用，它們支持及時的臨床決策。轉氨酶檢測產業的成長得益於技術進步和新興市場日益普及的雙重驅動。照護現場AST/GOT 設備的技術創新，加上人工智慧解讀的增強，正在縮短週轉時間並提高準確性。可攜式設備以及軟體主導的自動化技術，正在將檢測範圍從設備齊全的實驗室擴展到門診和鄉村地區。

另一個主要成長要素是全球肝病負擔的不斷加重。非酒精性脂肪肝病 (NAFLD)、病毒性肝炎和酒精性肝病的盛行率不斷上升，凸顯了定期進行轉氨酶篩檢的必要性。再加上人口老化和預防性醫療保健計劃的實施，推動了對可靠且經濟高效的肝臟生物標記檢測的需求。

2025年3月，歐洲藥品管理局 (EMA) 批准在臨床試驗中使用人工智慧 (AI) 工具 AIM-NASH，以評估代謝功能障礙核准性脂肪性肝炎 (MASH)（一種嚴重的脂肪肝疾病）的嚴重程度。 AIM-NASH 採用機器學習技術開發，使用來自 59 位病理學家的超過 100,000 條註釋進行訓練，並評估了九項大型臨床試驗中的 5,000 多例肝臟切片檢查。 EMA 人用藥物委員會確認，AIM-NASH 能夠可靠地從切片檢查中確定疾病活動性，且變異性低於目前通常依賴三位病理學家達成共識的標準。這項進展有望為臨床試驗中新治療方法的效用提供更明確的證據。

總體而言，受技術進步和醫療保健需求不斷成長的推動，全球轉氨酶檢測市場正在經歷重大轉型。將人工智慧 (AI) 融入診斷平台，可提高肝功能評估的準確性和效率，從而實現更早的發現和個人化治療策略。就地檢驗(POCT) 提供了一種快速且方便的檢測方式，擴大了肝臟診斷的可近性，尤其是在偏遠和服務不足的地區。此外，非侵入性診斷工具的發展正在減少對傳統切片檢查程序的依賴，鼓勵患者和醫療保健專業人員優先選擇微創方法。

由於此類創新改善了患者的治療效果並重塑了競爭格局，主要企業正在投資研發以保持市場領先地位。隨著對高效且易於獲取的肝病診斷的需求不斷成長，市場已準備好實現持續成長，為公司提供利用新興技術和滿足全球醫療保健生態系統不斷變化的需求的機會。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素
    • 肝病盛行率不斷上升
    • 診斷技術的進步
    • 擴大預防性醫療保健和篩檢項目
  • 市場限制因素分析
    • 低收入地區認知度較低
    • 成本和基礎設施障礙
  • 商業環境分析
    • 依因素（政治/法律、經濟/技術）進行 SWOT 分析
    • 波特五力分析

第4章 檢驗類業務分析

  • 轉氨酶檢測市場：檢測類型變化分析
  • ALT檢測
  • AST 測試
  • 多項轉氨酶檢測
  • 其他

第5章：技術業務分析

  • 轉氨酶檢測市場：技術變革分析
  • 自動分析儀
  • 半自動和手動系統
  • 照護現場(POC) 設備
  • 紙基/實驗室晶片平台
  • 其他

第6章：應用業務分析

  • 轉氨酶檢測市場：應用差異分析
  • 肝病的診斷與監測
  • 肝炎篩檢
  • 藥物性肝損傷（DILI）監測
  • 其他

第7章 最終用途業務分析

  • 轉氨酶檢測市場：最終用途變異分析
  • 醫院和診所
  • 診斷實驗室（集中檢測）
  • 研究機構
  • 家庭檢測
  • 其他

第8章 區域業務分析

  • 2024年及2033年轉氨酶檢測市佔率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業概況
  • 財務表現
  • 參與企業
    • 市場領導者
    • 轉氨酶檢測市佔率分析，2024年
    • 公司簡介
      • F. Hoffmann-La Roche AG
      • Abbott
      • Thermo Fisher Scientific
      • Siemens Healthineers
      • Danaher
      • Randox Laboratories Ltd
      • ELITechGroup
      • Horiba Medical
      • Alpha Laboratories
      • Laboratory Corporation of America Holdings (LabCorp)
      • Bio-Rad Laboratories, Inc.
      • bioMerieux
    • 戰略地圖
Product Code: GVR-4-68040-710-5

Transaminase Test Market Summary

The global transaminase test market size was estimated at USD 4.10 billion in 2024 and is projected to reach USD 7.81 billion by 2033, growing at a CAGR of 7.54% from 2025 to 2033. This market centers on rapid, accurate diagnostic platforms, such as AST (Aspartate Transaminase) and GOT (Glutamic Oxaloacetic Transaminase) assays, used extensively in liver function assessment, disease monitoring, and general health screening.

These platforms support timely clinical decisions, driven by increasing awareness of liver diseases and widespread integration into hospital, clinical, and point-of-care settings. The growth in the transaminase test industry is propelled by a combination of advancing technology and increasing access in emerging markets. Innovations in point-of-care AST/GOT devices-bolstered by AI-enabled interpretation-are reducing turnaround times and improving precision. Accessibility is expanding beyond well-resourced labs to outpatient clinics and rural settings, thanks to portable formats and software-driven automation.

Another major growth driver is the rising global burden of liver disease. The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), viral hepatitis, and alcohol-related liver conditions underscores the need for regular transaminase screening. Coupled with aging populations and preventive health programs, demand is mounting for reliable, cost-effective liver biomarker tests.

In March 2025, the European Medicines Agency (EMA) approved the use of the artificial intelligence (AI) tool AIM-NASH in clinical trials to assess the severity of metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease. Developed using machine learning, AIM-NASH was trained with over 100,000 annotations from 59 pathologists and evaluated more than 5,000 liver biopsies across nine large clinical trials. The EMA's human medicines committee confirmed that AIM-NASH can reliably determine disease activity from biopsies with less variability than the current standard, which typically relies on a consensus of three pathologists. This advancement is expected to enhance the clarity of evidence regarding the benefits of new treatments in clinical trials.

Overall, the global transaminase test market is experiencing significant transformation, driven by technological advancements and evolving healthcare needs. Integrating artificial intelligence (AI) into diagnostic platforms enhances the precision and efficiency of liver function assessments, enabling earlier detection and personalized treatment strategies. Point-of-care testing (POCT) expands access to liver diagnostics, particularly in remote and underserved regions, by providing rapid and convenient testing options. Furthermore, developing non-invasive diagnostic tools reduces reliance on traditional biopsy procedures, aligning with the growing preference for less invasive methods among patients and healthcare providers.

These innovations are improving patient outcomes and reshaping the competitive landscape, prompting key players to invest in research and development to stay at the forefront of the market. With the demand for efficient and accessible liver diagnostics continuing to rise, the market is well-positioned for sustained growth, offering opportunities for companies to leverage emerging technologies and meet the evolving needs of the global healthcare ecosystem.

Global Transaminase Test Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the transaminase test market on the basis of test type, technology, application, end use, and region:

  • Test Type Outlook (Revenue, USD Million, 2021 - 2033)
  • ALT Test
  • AST Test
  • Combined Transaminase Panels
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Automated Analyzers
  • Semi-Automated & Manual Systems
  • Point-of-Care (POC) Devices
  • Paper-Based / Lab-on-a-Chip Platforms
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Liver Disease Diagnosis & Monitoring
  • Hepatitis Screening
  • Drug-Induced Liver Injury (DILI) Monitoring
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories (centralized testing)
  • Research Institutes
  • Home Testing
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Prevalence of Liver Diseases
    • 3.4.2. Advancements in Diagnostic Technologies
    • 3.4.3. Expansion of Preventive Healthcare & Screening Programs
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Awareness in Low-Income Regions
    • 3.5.2. Cost & Infrastructure Barriers
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Test Type Business Analysis

  • 4.1. Transaminase Test Market: Test Type Movement Analysis
  • 4.2. ALT Test
    • 4.2.1. ALT Test Market, 2021 - 2033 (USD Million)
  • 4.3. AST Test
    • 4.3.1. AST Test Market, 2021 - 2033 (USD Million)
  • 4.4. Combined Transaminase Panels
    • 4.4.1. Combined Transaminase Panels Market, 2021 - 2033 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. Transaminase Test Market: Technology Movement Analysis
  • 5.2. Automated Analyzers
    • 5.2.1. Automated Analyzers Market, 2021 - 2033 (USD Million)
  • 5.3. Semi-Automated & Manual Systems
    • 5.3.1. Semi-Automated & Manual Systems Market, 2021 - 2033 (USD Million)
  • 5.4. Point-of-Care (POC) Devices
    • 5.4.1. Point-of-Care (POC) Devices Market, 2021 - 2033 (USD Million)
  • 5.5. Paper-Based / Lab-on-a-Chip Platforms
    • 5.5.1. Paper-Based / Lab-on-a-Chip Platforms Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Transaminase Test Market: Application Movement Analysis
  • 6.2. Liver Disease Diagnosis & Monitoring
    • 6.2.1. Liver Disease Diagnosis & Monitoring Market, 2021 - 2033 (USD Million)
  • 6.3. Hepatitis Screening
    • 6.3.1. Hepatitis Screening Market, 2021 - 2033 (USD Million)
  • 6.4. Drug-Induced Liver Injury (DILI) Monitoring
  • 6.5. Others
    • 6.5.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Transaminase Test Market: End Use Movement Analysis
  • 7.2. Hospitals & Clinics
    • 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Laboratories (centralized testing)
    • 7.3.1. Diagnostic Laboratories (centralized testing) Market, 2021 - 2033 (USD Million)
  • 7.4. Research Institutes
    • 7.4.1. Research Institutes Market, 2021 - 2033 (USD Million)
  • 7.5. Home Testing
    • 7.5.1. Home Testing Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Transaminase Test Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Transaminase Test market, 2021 - 2033 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Transaminase Test market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Transaminase Test market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Transaminase Test market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Transaminase Test Market Share Analysis, 2024
    • 9.3.3. Company Profiles
      • 9.3.3.1. F. Hoffmann-La Roche AG
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Abbott
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. Thermo Fisher Scientific
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Siemens Healthineers
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. Danaher
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Randox Laboratories Ltd
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. ELITechGroup
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Horiba Medical
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. Alpha Laboratories
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Laboratory Corporation of America Holdings (LabCorp)
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Bio-Rad Laboratories, Inc.
        • 9.3.3.11.1. Company Overview
        • 9.3.3.11.2. Financial Performance
        • 9.3.3.11.3. Product Benchmarking
        • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. bioMerieux
        • 9.3.3.12.1. Company Overview
        • 9.3.3.12.2. Financial Performance
        • 9.3.3.12.3. Product Benchmarking
        • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • TABLE 1 Transaminase Test Market- Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • TABLE 2 Global Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 3 Global Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 4 Global Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 5 Global Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 6 Global Transaminase Test Market, By Region, 2021 - 2033 (USD Million)
  • TABLE 7 Transaminase Test- Key Market Driver Analysis
  • TABLE 8 Transaminase Test- Key Market Restraint Analysis
  • TABLE 9 North America Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 10 North America Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 11 North America Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 12 North America Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 13 North America Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 14 U.S. Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 15 U.S. Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 16 U.S. Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 17 U.S. Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 18 Canada Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 19 Canada Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 20 Canada Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 21 Canada Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 22 Mexico Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 23 Mexico Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 24 Mexico Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 25 Mexico Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 26 Europe Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 27 Europe Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 28 Europe Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 29 Europe Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 30 Europe Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 31 Germany Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 32 Germany Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 33 Germany Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 34 Germany Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 35 Uk Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 36 Uk Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 37 Uk Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 38 Uk Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 39 France Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 40 France Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 41 France Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 42 France Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 43 Italy Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 44 Italy Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 45 Italy Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 46 Italy Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 47 Spain Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 48 Spain Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 49 Spain Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 50 Spain Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 51 Denmark Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 52 Denmark Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 53 Denmark Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 54 Denmark Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 55 Sweden Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 56 Sweden Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 57 Sweden Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 58 Sweden Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 59 Norway Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 60 Norway Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 61 Norway Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 62 Norway Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 63 Asia Pacific Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 64 Asia Pacific Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 65 Asia Pacific Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 66 Asia Pacific Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 67 Asia Pacific Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 68 Japan Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 69 Japan Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 70 Japan Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 71 Japan Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 72 China Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 73 China Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 74 China Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 75 China Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 76 India Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 77 India Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 78 India Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 79 India Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 80 Australia Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 81 Australia Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 82 Australia Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 83 Australia Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 84 South Korea Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 85 South Korea Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 86 South Korea Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 87 South Korea Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 88 Thailand Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 89 Thailand Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 90 Thailand Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 91 Thailand Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 92 Latin America Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 93 Latin America Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 94 Latin America Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 95 Latin America Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 96 Latin America Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 97 Brazil Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 98 Brazil Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 99 Brazil Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 100 Brazil Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 101 Argentina Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 102 Argentina Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 103 Argentina Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 104 Argentina Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 105 MEAMEA Transaminase Test Market, By Country, 2021 - 2033 (USD Million)
  • TABLE 106 MEA Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 107 MEA Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 108 MEA Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 109 MEA Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 110 South Africa Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 111 South Africa Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 112 South Africa Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 113 South Africa Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 114 Saudi Arabia Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 115 Saudi Arabia Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 116 Saudi Arabia Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 117 Saudi Arabia Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 118 UAE Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 119 UAE Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 120 UAE Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 121 UAE Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)
  • TABLE 122 Kuwait Transaminase Test Market, By Test Type, 2021 - 2033 (USD Million)
  • TABLE 123 Kuwait Transaminase Test Market, By Technology, 2021 - 2033 (USD Million)
  • TABLE 124 Kuwait Transaminase Test Market, By Application, 2021 - 2033 (USD Million)
  • TABLE 125 Kuwait Transaminase Test Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Transaminase Test Market Segmentation
  • FIG. 2 Global Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 3 Transaminase Test Market Dynamics
  • FIG. 4 Transaminase Test Market - Porter's Analysis
  • FIG. 5 Transaminase Test Market - PESTEL Analysis
  • FIG. 6 Transaminase Test Revenue Share, By Test Type, 2024 & 2033
  • FIG. 7 ALT Test Market, 2021 - 2033 (USD Million)
  • FIG. 8 AST Test Market, 2021 - 2033 (USD Million)
  • FIG. 9 Combined Transaminase Panels Market, 2021 - 2033 (USD Million)
  • FIG. 10 Others Market, 2021 - 2033 (USD Million)
  • FIG. 11 Transaminase Test Revenue Share, By Technology, 2024 & 2033
  • FIG. 12 Automated Analyzers Market, 2021 - 2033 (USD Million)
  • FIG. 13 Semi-Automated & Manual Systems Market, 2021 - 2033 (USD Million)
  • FIG. 14 Point-of-Care (POC) Devices Market, 2021 - 2033 (USD Million)
  • FIG. 15 Paper-Based / Lab-on-a-Chip Platforms Market, 2021 - 2033 (USD Million)
  • FIG. 16 Others Market, 2021 - 2033 (USD Million) Market, 2021 - 2033 (USD Million)
  • FIG. 17 Transaminase Test Revenue Share, By Application, 2024 & 2033
  • FIG. 18 Liver Disease Diagnosis & Monitoring Market, 2021 - 2033 (USD Million)
  • FIG. 19 Hepatitis Screening Market, 2021 - 2033 (USD Million)
  • FIG. 20 Drug-Induced Liver Injury (DILI) Monitoring Market, 2021 - 2033 (USD Million)
  • FIG. 21 Others Market, 2021 - 2033 (USD Million) Market, 2021 - 2033 (USD Million)
  • FIG. 22 Transaminase Test Revenue Share, By End Use, 2024 & 2033
  • FIG. 23 Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • FIG. 24 Diagnostic Laboratories (centralized testing) Market, 2021 - 2033 (USD Million)
  • FIG. 25 Research Institutes Market, 2021 - 2033 (USD Million)
  • FIG. 26 Home testing Market, 2021 - 2033 (USD Million)
  • FIG. 27 Others Market, 2021 - 2033 (USD Million)
  • FIG. 28 Transaminase Test Revenue Share, By Region, 2024 & 2033
  • FIG. 29 North America Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 30 U.S. Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 31 Canada Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 32 Mexico Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 33 Europe Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 34 Germany Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 35 UK Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 36 France Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 37 Italy Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 38 Spain Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 39 Denmark Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 40 Sweden Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 41 Norway Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 42 Asia Pacific Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 43 Japan Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 44 China Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 45 India Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 46 Australia Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 47 South Korea Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 48 Thailand Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 49 Latin America Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 50 Brazil Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 51 Argentina Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 52 MEA Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 53 South Africa Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 54 Saudi Arabia Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 55 UAE Transaminase Test Market, 2021 - 2033 (USD Million)
  • FIG. 56 Kuwait Transaminase Test Market, 2021 - 2033 (USD Million)